DDInter1326 DDInter927
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.
Inotuzumab ozogamicin is an antibody-drug conjugate using linker and cytotoxic drug technology similar to that developed for the ground-breaking treatment Mylotarg (), which was approved by the US FDA in 2000 for the treatment of acute myeloid leukaemia. Inotuzumab ozogamicin consists of a recombinant humanised IgG4 kappa CD22-targeting monoclonal antibody covalently attached to calicheamicin derivative, N-acetyl-gamma-calicheamicin dimethylhydrazide, which is a potent DNA-binding cytotoxic agent . Developed by Pfizer and UCB, inotuzumab ozogamicin was granted approval by EU in June 2017 followed by FDA on August 17th, 2017 for the treatment of adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia (ALL). ALL is a rapidly progressing cancer of the bone marrow that is associated with high mortality rates and low therapeutic response from standard chemotherapies in relasping conditions. In a randomized trial, inotuzumab ozogamicin displayed higher percentages of patients undergoing longer periods of complete remission with no evidence of disease in comparison to patients receiving alternative chemotherapy .
Olanzapine {u} (Compound) resembles {v} (Compound) Clozapine
Olanzapine {u} (Compound) resembles {v} (Compound) Pirenzepine
Olanzapine {u} (Compound) binds {v} (Gene) HTR7
Olanzapine {u} (Compound) upregulates {v} (Gene) NNT
Olanzapine {u} (Compound) palliates {v} (Disease) Gilles de la Tourette syndrome
Olanzapine {u} (Compound) downregulates {v} (Gene) ITGAE
Olanzapine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Metronidazole
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cetirizine
Olanzapine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Acarbose
Olanzapine {u} may lead to a major life threatening interaction when taken with {v} Potassium chloride
Olanzapine (Compound) resembles Clozapine (Compound)
Olanzapine (Compound) resembles Pirenzepine (Compound)
Olanzapine (Compound) binds HTR7 (Gene)
Olanzapine (Compound) upregulates NNT (Gene)
Olanzapine (Compound) palliates Gilles de la Tourette syndrome (Disease)
Olanzapine (Compound) downregulates ITGAE (Gene)
Olanzapine may cause a minor interaction that can limit clinical effects when taken with Metronidazole
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Cetirizine
Olanzapine may cause a moderate interaction that could exacerbate diseases when taken with Acarbose
Olanzapine may lead to a major life threatening interaction when taken with Potassium chloride